Ipamorelin vs Pegvisomant
Research Verdict
Pegvisomant is the stronger research reference for the stated comparison criteria. Pegvisomant (Somavert): FDA approved (2003) GH receptor antagonist for acromegaly, Phase 3 data (Trainer 2000, NEJM), well-characterized in thousands of patients.
Quick Answers
Which is better, Ipamorelin or Pegvisomant?
Pegvisomant is the stronger research reference for the stated comparison criteria. Pegvisomant (Somavert): FDA approved (2003) GH receptor antagonist for acromegaly, Phase 3 data (Trainer 2000, NEJM), well-characterized in thousands of patients.
What is the key difference between Ipamorelin and Pegvisomant?
Pegvisomant blocks GH receptor signaling to reduce IGF-1 in acromegaly; ipamorelin stimulates GH release - they have opposite pharmacological actions on the GH axis, making this comparison about mechanism education rather than therapeutic choice.
Evidence Comparison
Pegvisomant (Somavert): FDA approved (2003) GH receptor antagonist for acromegaly, Phase 3 data (Trainer 2000, NEJM), well-characterized in thousands of patients. Ipamorelin: Phase 2 post-operative ileus only. Pegvisomant has overwhelmingly stronger clinical evidence.
Evidence Context Favoring Ipamorelin
GH secretion research where selective GH pulsatility stimulation is the goal.
Evidence Context Favoring Pegvisomant
Acromegaly treatment, GH excess, or research requiring IGF-1 suppression - pegvisomant is the FDA-approved standard of care.
Side-by-Side Snapshot
| Evidence grade | Ipamorelin: Level B Pegvisomant: Level A |
|---|---|
| Research status | Ipamorelin: Phase 2 Pegvisomant: FDA Approved |
| Primary category | Ipamorelin: Growth Hormone Pegvisomant: Growth Hormone |
| Cited studies | Ipamorelin: 3 Pegvisomant: 2 |